HIV generic drug for babies distributed in Africa, says
UNITAID
Send a link to a friend
[July 05, 2021]
DUBAI (Reuters) - Aid agencies have
distributed a strawberry-flavoured tablet for children living with HIV
in six African countries, the first generic pediatric version of a key
anti-retroviral, global health agency UNITAID said on Sunday.
|
UNITAID and Clinton Health Access Initiative (CHAI) funding procured
100,000 packs of the dolutegravir formulation across Nigeria,
Malawi, Uganda, Kenya, Zimbabwe and Benin, UNITAD's spokesman Herve
Verhoosel said in statement to Reuters.
Some 1.8 million children worldwide live with HIV, but only half
receive any treatment, often hard to administer due to the bitter
taste or incorrectly dosed by crushing adult pills. Some 100,000
children die of AIDS annually.
"With the recent delivery of the formulation in those 6 first
countries, this project is now reality," Verhoosel, who is visiting
the United Arab Emirates, said of the initiative first announced
last December.
He said this procurement is designed to kickstart demand and that
major donors have "rapidly moved to sustainable onward procurement,
which will enable national scale-up and widespread access for all
eligible children at an unprecedented pace".
The first-line HIV treatment is recommended by the World Health
Organization from the age of four weeks and 3 kilos (6.6 pounds),
but it had been out of reach for babies because of the lack of
appropriate formulations.
[to top of second column] |
UNITAID and CHAI had reached a
pricing agreement with the generic drugmakers
Viatris and Macleods for the dispersible
pediatric formulation of dolutegravir.
The estimated cost for combination therapy will
now be some $120 for a child's annual treatment,
against $480 currently, making it a
"game-changer" for poorer countries, UNITAID
said.
Verhoosel said a partnership with Medicines
Patent Pool allowed for voluntary licensing
agreements across 121 countries.
(Writing by Ghaida Ghantous;Editing by Elaine
Hardcastle)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content
|